Movement Alert｜Insmed Pre-Market Rise 15.02%, quarterly results topped expectations with revenue surging ahead of forecasts

Market Focus10-29

On October 29, Insmed rose 15.02% in Pre-Market Trading, trading at $110.001/share, with turnover of $1.2177 million.

The move was driven by the company’s latest quarterly results released the same day before the market, with consensus ahead of the report pointing to revenue of about $502 million, up 334.01% year over year, and adjusted EPS of negative $0.38, improving 71.94% from a year earlier.

Leading into the report, Brinsupri remained the main growth engine. In the prior quarter, total revenue reached $425.5 million, up from $107.4 million a year earlier, while adjusted loss narrowed to $0.06 per share from $1.70. Brinsupri delivered about $309 million in sales, and management had raised full-year Brinsupri guidance to $1.25 billion-$1.40 billion while reiterating Arikayce guidance of $450 million-$470 million. Recent catalysts also included the Japan launch of a 25 mg Brinsupri tablet and FDA priority review for Arikayce’s supplemental filing, reinforcing the commercial and pipeline backdrop.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment